drugset / Trial / NCT02532738
The Efficiency of MSC in Refractory Crohn's Disease
Phase 2/3
Unknown
3 enrolled
Sixth Affiliated Hospital, Sun Yat-sen University
Nanfang Hospital, Southern Medical University · collabThird Affiliated Hospital, Sun Yat-Sen University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The investigators' preliminary study indicates that MSC is effective therapy in treating IBD. But the standard treatment is still lacking and the effect is not stable in IBD patients. This study is to explore the efficacy and standard strategy when using MSC in refractory IBD.
Timeline
- Start
- 2016-01
- Primary completion
- 2018-11
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MSC | Unknown | 3e+06 cells/kg | — |
| Subject | MSC | Unknown | 6e+06 cells/kg | — |
| Background | AZA | Unknown | — | — |
| Background | Infliximab | Monoclonal antibody | — | — |
| Background | MERCAPTOPURINE ANHYDROUS | Small molecule | — | — |
| Background | Thalidomide | Other / unclassified | — | — |